KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Shares Outstanding (2016 - 2025)

Arbutus Biopharma's Shares Outstanding history spans 15 years, with the latest figure at $190.0 million for Q4 2024.

  • For Q4 2024, Shares Outstanding rose 11.83% year-over-year to $190.0 million; the TTM value through Dec 2024 reached $190.0 million, up 11.83%, while the annual FY2024 figure was $190.0 million, 11.83% up from the prior year.
  • Shares Outstanding for Q4 2024 was $190.0 million at Arbutus Biopharma, up from $169.9 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $190.0 million in Q4 2024 and bottomed at $1.2 million in Q3 2020.
  • The 5-year median for Shares Outstanding is $145.0 million (2021), against an average of $120.9 million.
  • The largest annual shift saw Shares Outstanding tumbled 98.37% in 2021 before it soared 12683.01% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $89.7 million in 2020, then soared by 61.67% to $145.0 million in 2021, then increased by 8.6% to $157.5 million in 2022, then rose by 7.88% to $169.9 million in 2023, then rose by 11.83% to $190.0 million in 2024.
  • Per Business Quant, the three most recent readings for ABUS's Shares Outstanding are $190.0 million (Q4 2024), $169.9 million (Q4 2023), and $165.1 million (Q1 2023).